I do follow Biotech industry which is showing great promise with new products launches recently.
According to Precedence Research, the global biotechnology market size was valued at USD 1,224.31 billion in 2022 and is anticipated to surpass around USD 3,210.71 billion by 2030. The global biotechnology market is growing at a CAGR of 12.8% from 2023 to 2030
As a small time retail investor I do not and cannot take huge risk when it comes to Biotech so I focus only on certain research areas like – cancer vaccine, Alzheimer’s.
One such Biotech company is INmune Bio (NASDAQ: INMB). INmune Bio presented at recent CTAD conference;
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, highlights some important findings from data presented at the 16th annual Clinical Trial in Alzheimer’s Disease (CTAD) to be held October 24-27 in Boston, MA.
INmune is enrolling AD patients into a global, blinded, randomized Phase II trial. “The Phase Ib trial was designed to demonstrate that XPro™ reverses neuroinflammation and has been confirmed by previously presented data,” said CJ Barnum Ph.D., VP of CNS Drug Development at INmune Bio. “The trial further demonstrated many incremental downstream benefits of reversing neuroinflammation with XPro™. We continue to harvest information from the extensive data collected from the trial to improve our understanding of the role of neuroinflammation in AD, the mechanism-of-action (MOA) of XPro™, and provide insight into future clinical trial design.”
INmune has shown in Phase 1 and now in Phase1b study that this is on the right path to an effective treatment for Alzheimer’s. Improvement in the pathologies at the earliest stages of the disease is proof that neuro-inflammation is a driving force behind the disease as opposed to a symptom.
More on INmune Bio in coming articles. Meanwhile, do leave a comment and subscribe for more updates…
Busy And Useful 